Gene · 23765
Papers3,930
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
741 to 760 of 3,930
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| iNKT17 cells play a pathogenic role in ethinylestradiol-induced cholestatic hepatotoxicity. | Arch Toxicol | 2023 | 36329302 | PubTator, text mining | PubMed |
| How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management. | Curr Rheumatol Rep | 2023 | 36308677 | PubTator, text mining | PubMed |
| TRAF3IP2-IL-17 Axis Strengthens the Gingival Defense against Pathogens. | J Dent Res | 2023 | 36281065 | PubTator, text mining | PubMed |
| Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study. | Rheumatology (Oxford) | 2023 | 36130275 | PubTator, text mining | PubMed |
| IL-17A promotes Helicobacter pylori-induced gastric carcinogenesis via interactions with IL-17RC. | Gastric Cancer | 2023 | 36125689 | PubTator, text mining | PubMed |
| The emerging role of IL-23 in asthma and its clinical implications. | Expert Rev Clin Immunol | 2023 | 36106675 | PubTator, text mining | PubMed |
| Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. | Rheumatology (Oxford) | 2023 | 36102818 | PubTator, text mining | PubMed |
| N-glycoproteomics reveals distinct glycosylation alterations in NGLY1-deficient patient-derived dermal fibroblasts. | J Inherit Metab Dis | 2023 | 36102038 | PubTator, text mining | PubMed |
| Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells. | J Allergy Clin Immunol | 2023 | 35963455 | PubTator, text mining | PubMed |
| A comprehensive network map of IL-17A signaling pathway. | J Cell Commun Signal | 2023 | 35838944 | PubTator, text mining | PubMed |
| Disease-specific expansion of CD29+IL-17RA+ T effector cells possessing multiple signalling pathways in spondyloarthritis. | Rheumatology (Oxford) | 2023 | 35799366 | PubTator, text mining | PubMed |
| IL-17 and IL-17-producing cells in protection versus pathology. | Nat Rev Immunol | 2023 | 35790881 | PubTator, text mining | PubMed |
| Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. | Mol Carcinog | 2023 | 35781709 | PubTator, text mining | PubMed |
| Persistent discharge or edema after endoscopic sinus surgery in patients with chronic rhinosinusitis is associated with a type 1 or 3 endotype. | Int Forum Allergy Rhinol | 2023 | 35670482 | PubTator, text mining | PubMed |
| Sex Differences in Neurodevelopmental Disorders: A Key Role for the Immune System. | Curr Top Behav Neurosci | 2023 | 35435643 | PubTator, text mining | PubMed |
| The Airway Microbiome-IL-17 Axis: a Critical Regulator of Chronic Inflammatory Disease. | Clin Rev Allergy Immunol | 2023 | 35275333 | PubTator, text mining | PubMed |
| Defective ORF8 dimerization in SARS-CoV-2 delta variant leads to a better adaptive immune response due to abrogation of ORF8-MHC1 interaction. | Mol Divers | 2023 | 35243596 | PubTator, text mining | PubMed |
Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang. | Ann Rheum Dis | 2023 | 34172504 | PubTator, text mining | PubMed |
Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial'. | Ann Rheum Dis | 2023 | 34172501 | PubTator, text mining | PubMed |
| Systematic characterization of extracellular glycoproteins using mass spectrometry. | Mass Spectrom Rev | 2023 | 34047389 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23765/papers?page=38